Abstract This opinion piece, published in Frontiers in Cardiovascular Medicine, proposes a significant update to the classification of Cardiorenal Syndrome (CRS). By introducing Type 6 CRS (Chronic Secondary CRS), the authors aim to better categorize systemic diseases like diabetes and hypertension that simultaneously degrade both heart and kidney function over time.
Introduction: The Need for Refinement
Since 2008, the medical community has relied on a five-type classification system for CRS. Types 1 through 4 describe a "domino effect" where failure in one organ (acute or chronic) leads to failure in the other. Type 5 was traditionally a "catch-all" category for systemic diseases—such as sepsis or diabetes—that affect both organs simultaneously.
However, the authors argue that Type 5 is overly broad. It conflates sudden, acute events like sepsis with slow, chronic processes like diabetes. Given that the pathophysiology and treatment for an acute "cytokine storm" differ vastly from chronic tissue scarring (fibrosis), a sixth, distinct category is necessary for clinical precision.
Proposed Classification: Type 5 vs. Type 6
The authors propose splitting "Secondary CRS" into two distinct subtypes to create a more logical, symmetrical framework:
- Type 5 (Acute Secondary CRS): Triggered by acute systemic events such as sepsis or acute intoxication.
- Type 6 (Chronic Secondary CRS): Triggered by chronic systemic conditions including diabetes, hypertension, obesity, and lupus.
In Type 6, a systemic "third party" attacks both organs simultaneously, making it difficult to determine which organ failed first. This "chronic co-impairment" acknowledges the complex, parallel degradation of both systems.
Pathophysiology: The Fibrosis Pathway
The defining mechanism for Type 6 CRS is a common fibrosis pathway. Chronic inflammation leads to the secretion of extracellular matrix proteins, which eventually causes scarring in both the heart and kidneys. While hemodynamic changes and the renin-angiotensin-aldosterone system (RAAS) remain important, the authors identify chronic fibrosis as the primary "vicious cycle" driving this subtype.
Diagnosis and Therapeutic Shift
To improve clinical management, the authors suggest moving beyond patient history toward objective diagnostic tools:
- Biomarkers: Markers of fibrosis such as Galectin-3 (Gal-3), NGAL, and ST-2 are proposed for more accurate diagnosis.
- Imaging: LGE-MRI and kidney biopsies can help identify myocardial fibrosis and tubulointerstitial scarring, respectively.
Treatment strategies should shift toward "anti-fibrosis therapy" and unified co-treatment. Rather than treating the heart and kidneys in isolation—which can lead to conflicting interventions—Type 6 encourages the use of drugs with multi-organ benefits, such as SGLT-2 inhibitors and ARNIs.
Limitations and Future Directions
As a proposed classification, Type 6 requires large-scale prospective studies to validate whether this categorization improves clinical outcomes. Furthermore, many clinical trials currently exclude patients with advanced chronic kidney disease, limiting the data available for this population. The authors call for increased cross-specialty cooperation and the inclusion of these patients in future research to refine the use of biomarkers and therapeutic interventions.
Summary updated